Skip to main
MIRM
MIRM logo

MIRM Stock Forecast & Price Target

MIRM Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mirum Pharmaceuticals Inc. reported net sales revenue for its product LIVMARLI of $64.1 million in the fourth quarter of 2024, marking an 8.4% growth from the previous quarter and a significant 54.5% increase year-over-year. The company anticipates continued growth from LIVMARLI's indications for Alagille syndrome and progressive familial intrahepatic cholestasis, with a potential for a substantial global market expansion based on positive clinical data. Additionally, Mirum is positioned favorably as a cash-flow positive entity with numerous clinical milestones, including the anticipated launch of its bile acid products for cerebrotendinous xanthomatosis, suggesting further revenue growth opportunities.

Bears say

Mirum Pharmaceuticals Inc faces significant challenges that negatively impact its financial outlook, including the risk of sales growth for its approved products, Livmarli and volixibat, falling well below expectations. The company reported a net loss of $87.9 million for FY2024, primarily driven by high research and development expenses totaling $140.6 million and significant selling, general, and administrative expenses of $202.2 million, raising concerns about future profitability and the potential need for additional capital. Furthermore, uncertainties surrounding regulatory approvals, market competition, and the viability of its late-stage pipeline could hinder commercial success and exacerbate financial strain, potentially leading to shareholder dilution.

MIRM has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mirum Pharmaceuticals Inc (MIRM) Forecast

Analysts have given MIRM a Buy based on their latest research and market trends.

According to 16 analysts, MIRM has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mirum Pharmaceuticals Inc (MIRM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.